Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT03460808 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT03460808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03460808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Lead sponsor
Peking University People's Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 10, 2018
Completion date
January 1, 2023
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia